Attenuation of nicotine-induced rewarding effects in A2A knockout mice

Neuropharmacology

Volumn 51, Issue 3, 2006, Pages 631-640

  Castañé, Anna ^a   Soria, Guadalupe ^a   Ledent, Catherine ^b   Maldonado, Rafael ^a   Valverde, Olga ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

A2A adenosine receptors; Dopamine; Knockout; Microdialysis; Nicotine

Indexed keywords

ADENOSINE A2A RECEPTOR; DOPAMINE; MECAMYLAMINE; NICOTINE; NICOTINIC RECEPTOR BLOCKING AGENT; SACCHARIN; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; AVERSION; BEHAVIOR; CONTROLLED STUDY; DNA MODIFICATION; DRINKING; FEMALE; GENOTYPE; HOT PLATE TEST; LOCOMOTION; MICRODIALYSIS; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; TASTE AVERSION; WITHDRAWAL SYNDROME;

ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; CONDITIONING (PSYCHOLOGY); DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, KNOCKOUT; MICRODIALYSIS; MOTOR ACTIVITY; NICOTINE; NICOTINIC AGONISTS; NUCLEUS ACCUMBENS; RECEPTOR, ADENOSINE A2A; REWARD; SUBSTANCE WITHDRAWAL SYNDROME; TASTE;

EID: 33747083178     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2006.05.005     Document Type: Article

References (50)

1. Agnati L.F., Ferré S., Lluis C., Franco R., and Fuxe K. Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55 (2003) 509-550
2. Andersson M., Usiello M., Borgkvist A., Pozzi L., Dominguez C., Fienberg A.A., Svenningsson P., Fredholm B.B., Borrelli E., Greengard P., and Fisone G. Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J. Neurosci. 25 (2005) 8432-8438
3. Bespalov A.Y., Dravolina O.A., Sukhanov I., Zakharova E., Blokhina E., Zvartau E., Danysz W., Van Heeke G., and Markou A. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49 (2005) 167-178
4. Brown C.R., and Benowitz N.L. Caffeine and cigarette smoking: behavioral, cardiovascular, and metabolic interactions. Pharmacol. Biochem. Behav. 34 (1989) 565-570
5. Castañé A., Valjent E., Ledent C., Parmentier M., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 43 (2002) 857-867
6. Celik E., Uzbay I.T., and Karakas S. Caffeine and amphetamine produce cross-sensitization to nicotine-induced locomotor activity in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 30 (2006) 50-55
7. d'Alcantara P., Ledent C., Swillens S., and Schiffmann S.N. Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107 (2001) 455-464
8. Damaj M.I., Kao W., and Martin B.R. Characterization of spontaneous and precipitated nicotine withdrawal in the mouse. J. Pharmacol. Exp. Ther. 307 (2003) 526-534
9. Di Chiara G., and Imperato A. Drugs abused by humans preferentially increase synaptic DA concentrations in the mesolimbic system of freely moving rats. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 5274-5278
10. Díaz-Cabiale Z., Vivo M., Del Arco A., O'Connor W.T., Harte M.K., Muller C.E., Martínez E., Popoli P., Fuxe K., and Ferré S. Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett. 324 (2002) 154-158
11. Fredholm B.B., Ijzerman A.P., Jacobson K.A., Klotz K.N., and Linden J. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53 (2001) 527-552
12. Gasior M., Jaszyna M., Peters J., and Goldberg S.R. Changes in the ambulatory activity and discriminative stimulus effects of psychostimulant drugs in rats chronically exposed to caffeine: effect of caffeine dose. J. Pharmacol. Exp. Ther. 295 (2000) 1101-1111
13. Gommans J., Stolerman I.P., and Shoaib M. Antagonism of the discriminative and aversive stimulus properties of nicotine in C57BL/6J mice. Neuropharmacology 39 (2000) 2840-2847
14. Gould T.D., and Manji H.K. DARPP-32: a molecular switch at the nexus of reward pathway plasticity. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 253-254
15. Grabus S.D., Martin B.R., Batman A.M., Tyndale R.F., Sellers E., and Damaj M.I. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology 178 (2005) 1831-1892
16. Hamada M., Hendrick J.P., Ryan G.R., Kuroiwa M., Higashi H., Tanaka M., Nairn A.C., Greengard P., and Nishi A. Nicotine regulates DARPP-32 phosphorylation at multiple sites in neostriatal neurons. J. Pharmacol. Exp. Ther. 315 (2005) 872-878
17. Hamada M., Higashi H., Nairn A.C., Greengard P., and Nishi A. Differential regulation of dopamine D1 and D2 signaling by nicotine in neostriatal neurons. J. Neurochem. 90 (2004) 1094-1103
18. Hildebrand B.E., Nomikos G.G., Hertel P., Schilstrom B., and Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res. 779 (1998) 214-225
19. Homayounfar H., Jamali-Raeufy N., Sahebgharani M., and Zarrindast M.R. Adenosine receptor mediates nicotine-induced antinociception in formalin test. Pharmacol. Res. 51 (2005) 197-203
20. Isola R., Vogelsberg V., Wemlinger T.A., Neff N.H., and Hadjiconstantinou M. Nicotine abstinence in the mouse. Brain Res. 850 (1999) 189-196
21. Kane J.K., Hwang Y., Konu O., Loughlin S.E., Leslie F.M., and Li M.D. Regulation of Homer and group I metabotropic glutamate receptors by nicotine. Eur. J. Neurosci. 21 (2005) 1145-1154
22. Koob G.F., and Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology 24 (2001) 97-129
23. Kull B., Svenningsson P., and Fredholm B.B. Adenosine A(2A) receptors are colocalized with and activate g(olf) in rat striatum. Mol. Pharmacol. 58 (2000) 771-777
24. Laviolette S.R., and Van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat. Rev. Neurosci. 5 (2004) 55-65
25. Le Novère N., Corringer P.J., and Changeux J.P. The diversity of subunit composition in nAChRs: evolutionary origins, physiologic and pharmacologic consequences. J. Neurobiol. 53 (2002) 447-456
26. Ledent C., Vaugeois J.M., Schiffmann S.N., Pedrazzini T., El Yacoubi M., Vanderhaeghen J.J., Costentin J., Heath J.K., Vassart G., and Parmentier M. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature 388 (1997) 674-678
27. Maldonado R., Saiardi A., Valverde O., Samad T.A., Roques B.P., and Borrelli E. Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature 388 (1997) 586-589
28. Mansvelder H.D., De Rover M., McGehee D.S., and Brussaard A.B. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. Eur. J. Pharmacol. 480 (2003) 117-123
29. Nishi A., Liu F., Matsuyama S., Hamada M., Higashi H., Nairm A.C., and Greengard P. Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 1322-1327
30. Paterson N.E., and Markou A. The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology 179 (2005) 255-261
31. Paterson N.E., Semenova S., Gasparini F., and Markou A. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology 167 (2003) 257-264
32. Paxinos G., and Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates vol. 1 (1997), Academic, San Diego pp. 268-272
33. Pontieri F.E., Tanda G., Orzi F., and Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature 382 (1996) 255-257
34. Robledo P., Mendizábal V., Ortuño J., de la Torre R., Kieffer B.L., and Maldonado R. The rewarding properties of MDMA are preserved in mice lacking mu-opioid receptors. Eur. J. Neurosci. 20 (2004) 853-858
35. Rodrigues R.J., Alfaro T.M., Rebola N., Oliveira C.R., and Cunha R.A. Co-localization and functional interaction between adenosine A(2A) and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92 (2005) 433-441
36. Shoaib M. Is dopamine important in nicotine dependence?. J. Physiol. Paris 92 (1998) 9-33
37. Shoaib M., Swanner L.S., Yasar S., and Goldberg S.R. Chronic caffeine exposure potentiates nicotine self-administration in rats. Psychopharmacology 142 (1999) 327-333
38. Simonin F., Valverde O., Smadja C., Slowe S., Kitchen I., Dierich A., Le Meur M., Roques B.P., Maldonado R., and Kieffer B.L. Disruption of the kappa-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective kappa-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17 (1998) 886-897
39. Soria G., Castañé A., Berrendero F., Ledent C., Parmentier M., Maldonado R., and Valverde O. Adenosine A2A receptors are involved in physical dependence and place conditioning induced by THC. Eur. J. Neurosci. 20 (2004) 2203-2213
40. Soria G., Castañé A., Ledent C., Parmentier M., Maldonado R., and Valverde O. The lack of A(2A) adenosine receptors diminishes the reinforcing efficacy of cocaine. Neuropsychopharmacology 31 (2006) 978-987
41. Soria G., Mendizábal V., Touriño C., Robledo P., Maldonado R., and Valverde O. Lack of CB1 cannabinoid receptor impairs cocaine self-administration. Neuropsychopharmacology 30 (2005) 1670-1680
42. Sudakov S.K., Rusakova I.V., and Medvedeva O.F. Effect of chronic caffeine consumption on changes in locomotor activity of WAG/G and Fischer-344 rats induced by nicotine, ethanol, and morphine. Bull. Exp. Biol. Med. 136 (2003) 563-565
43. Sung K.W., Choi S., and Lovinger D.M. Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J. Neurophysiol. 86 (2001) 2405-2412
44. Svenningsson P., Lindskog M., Ledent C., Parmentier M., Greengard P., Fredholm B.B., and Fisone G. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 1856-1860
45. Swanson J.A., Lee J.W., and Hopp J.W. Caffeine and nicotine: a review of their joint use and possible interactive effects in tobacco withdrawal. Addict. Behav. 19 (1994) 229-256
46. Tessari M., Pilla M., Andreoli M., Hutcheson D.M., and Heidbreder C.A. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking. Eur. J. Pharmacol. 499 (2004) 121-133
47. Valjent E., Pascoli V., Svenningsson P., Paul S., Enslen H., Corvol J.C., Stipanovich A., Caboche J., Lombroso P.J., Nairn A.C., Greengard P., Herve D., and Girault J.A. Regulation of a protein phosphatase cascade allows convergent dopamine and glutamate signals to activate ERK in the striatum. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 491-496
48. Wonnacott S. Presynaptic nicotinic ACh receptors. Trends Neurosci. 20 (1997) 92-98
49. Wonnacott S., Sidhpura N., and Balfour D.J. Nicotine: from molecular mechanisms to behaviour. Curr. Opin. Pharmacol. 5 (2005) 53-59
50. Zocchi A., Girlanda E., Varnier G., Sartori I., Zanetti L., Wildish G.A., Lennon M., Mugnaini M., and Heidbreder C.A. Dopamine responsiveness to drugs of abuse: A shell-core investigation in the nucleus accumbens of the mouse. Synapse 50 (2003) 293-302